4-(乙硫基)吡啶 | 13669-34-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-(乙硫基)吡啶
• 英文名称: 4-(ethylsulfanyl)pyridine
• 英文别名: 4-(ethylthio)pyridine；etpy；4-ethylsulfanyl-pyridine；4-Aethylmercapto-pyridin；4-ethylsulfanylpyridine
• CAS: 13669-34-6
• 化学式: C₇H₉NS
• 分子量: 139.221
• InChiKey: KTHHGWBSZFCEPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(乙硫基)吡啶 在 N-氯代丁二酰亚胺 、 N,N-二甲基苯胺 作用下， 以 四氯化碳 、 xylene 为溶剂， 反应 4.0h， 生成 4-乙烯基硫基吡啶
  参考文献：
  名称：

  Sulfurization of Azines; Part IX. (1-Chloroalkylthio)-azines

  摘要：

  DOI：

  10.1055/s-1986-31795
• 作为产物：
  描述：

  1-(4-ethylsulfanyl-4H-pyridin-1-yl)-2,6-dimethylpyridin-4-one 以60%的产率得到
  参考文献：
  名称：

  SAMMES M. P.; LEUNG C. W. F.; MAK C. K.; KATRITZKY A. R., J. CHEM. SOC. PERKIN TRANS., 1981, PART 1, NO 5, 1589-1590

  摘要：

  DOI：

文献信息

• HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180072717A1

  公开（公告）日：2018-03-15

  The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中R 1 ，R 2 ，X，Y和HET如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和紊乱的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASE
  申请人：UNIV CALIFORNIA

  公开号：WO2013056163A1

  公开（公告）日：2013-04-18

  Disclosed herein inter alia are Boron containing compounds and methods for treating infections related to antibiotic resistant microorganisms.

  本公开涉及含硼化合物和治疗与抗生素耐药微生物相关感染的方法。
• Synthetic applications of N–N linked heterocycles. Part 12. The preparation of 4-alkylthio- and 4-arylthio-pyridines by regiospecific attack of thioalkoxide lons on N-(4-oxopyridin-1-yl)pyridinium salts
  作者：Michael P. Sammes、Christopher W. F. Leung、Chi Keung Mak、Alan R. Katritzky

  DOI：10.1039/p19810001585

  日期：——

  Thiolate ions add regiospecifically to N-(4-oxopyridin-1-yl)pyridinium salts (2)–(7) to give in good to excellent yields only the 1,4-dihydropyridine adducts (8)–(13), regardless of whether or not the pyridone moiety carries substituents for sterically shielding the 2- and 6-positions of the pyridinium ring. The addition is believed to be thermodynamically controlled. Decomposition of the dihydro-adducts

  硫醇离子对N-（4-氧代吡啶-1-基）吡啶鎓盐（2）-（7）呈区域特异性添加，仅产生1,4-二氢吡啶加合物（8）-（13）即可获得优异的优良收率吡啶酮部分是否带有取代基以立体屏蔽吡啶鎓环的2位和6位。据信该添加是热力学控制的。在自由基条件下或通过热解分解二氢加合物，尽管2-甲基加合物（9）反应失败，但吡啶4-基硫醚（14）和（16）的收率很高。还描述了6-甲基-4-氧杂吡喃-2-羧酸的改进的合成。
• Optically-Detectable Enzyme Substrates and Their Method of Use
  申请人：Life Technologies Corporation

  公开号：US20160139135A1

  公开（公告）日：2016-05-19

  The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a β-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a β-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a β-lactmase or instructions for using the components in an assay.

  本发明涉及一种酶底物化合物，与酶反应后产生可检测的响应，例如光学可检测的响应。具体而言，这些化合物在检测样品中β-内酰胺酶的存在方面具有实用性。除了这些化合物外，还公开了用于分析样品中β-内酰胺酶存在的方法，例如，作为表达包括编码β-内酰胺酶序列的核酸序列的指示器。还公开了包括这些化合物和额外组分的试剂盒，例如细胞、抗体、β-内酰胺酶或使用这些组分进行检测的说明书。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。